Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00826618
Recruitment Status : Completed
First Posted : January 22, 2009
Results First Posted : August 26, 2014
Last Update Posted : August 26, 2014
Genentech, Inc.
Information provided by (Responsible Party):
Thomas Albini, University of Miami

Brief Summary:

Uveitic Cystoid Macular Edema (CME) is a major cause of visual loss associated with uveitis. Systemic and/or local corticosteroid therapy and systemic immunosuppression with steroid-sparing agents such as cyclosporine, methotrexate, azathioprine, or others, effectively treats uveitis and associated CME in many patients. However, in many cases, CME persists in spite of adequate suppression of uveitis. No consensus exists on how best to treat such cases. The further addition of immunosuppressive agents appears to have little effect on this form of CME. Oral corticosteroids are useful, but high dosage and prolonged use can be associated with serious side-effects. Periocular and intravitreal corticosteroid injections are associated with well-known, significant side effects such as glaucoma and cataract formation.

Vascular endothelial growth factor (VEGF) is suspected to play a role in the loss of vascular integrity in the eye and known to be induced by inflammatory cytokines, such as interleukin interleukin (IL)-1β and IL-6, which are elevated intraocularly in uveitis. In addition, it has been demonstrated that aqueous VEGF concentrations are statistically significantly higher in those uveitis patients with CME than those without CME. Inhibition of inappropriate VEGF activity is a potential approach to treatment of CME in uveitis given our current knowledge of the pathophysiology of this condition and also because of the clinical need for additional treatment options for these patients. Ranibizumab, a recombinant, humanized monoclonal antibody antigen-binding fragment (Fab) that neutralizes all active forms of VEGF-A, would target this pathway and may be useful in cases of persistent CME in uveitis patients.

The objective of this study is to determine if an anti-VEGF agent, Lucentis, is safe and effective in leading to regression of macular edema due to chronic non-infectious uveitis in patients with well-controlled uveitis.

Condition or disease Intervention/treatment Phase
Uveitic Cystoid Macular Edema Drug: ranibizumab Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Study of Ranibizumab (Lucentis) for Uveitic Cystoid Macular Edema
Study Start Date : June 2008
Actual Primary Completion Date : September 2012
Actual Study Completion Date : September 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Edema
Drug Information available for: Ranibizumab

Arm Intervention/treatment
Experimental: Ranibizumab Drug: ranibizumab
This is an open-label, Phase I study of intravitreally administered 0.5mg ranibizumab in subjects with uveitic CME.
Other Name: Lucentis

Primary Outcome Measures :
  1. Change From Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS at 4 Meters) at 12 Months. [ Time Frame: 1 year ]
    Mean change in best corrected visual acuity (assessed by the ETDRS chart at 4 m) from baseline at 12 months following first intravitreal injection of ranibizumab was 12.2 ETDRS letters (P = 0.015).

Secondary Outcome Measures :
  1. The Mean Change in Best Corrected Visual Acuity (BCVA) (Assessed by the ETDRS Chart at 4 Meters) From Baseline at 12 Months Will be Computed With a T-test. [ Time Frame: 1 year ]
  2. The Percentage of Patients With 15 Letters (3 Lines) of Visual Acuity Improvement at 30, 60, 90, 120 Days, and 12 Months. [ Time Frame: 1 year ]
  3. The Mean Change in Foveal Retinal Thickness From Baseline at 7 Days, and at 30, 60, 90, 120 Days, and 12 Months Will be Computed Using a T-test. [ Time Frame: 1 year ]
  4. The Incidence of Ocular and Non-ocular Adverse Events Will be Evaluated Through Month 24. [ Time Frame: 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Subjects will be eligible if the following criteria are met:

  1. Ability to provide written informed consent and comply with study assessments for the full duration of the study.
  2. Age > 18 years
  3. Non-infectious uveitis in study eye.
  4. Stable anti-uveitis medical regimen for at least one month prior to injection and controlled uveitis in the judgment of the investigator.
  5. Vision 20/40 or worse in study eye.
  6. Cystoid Macular Edema (CME) on fluorescein angiography (FA)
  7. Optical Coherence Tomography (OCT) demonstrating thickness greater than 300 microns in the central subfield.
  8. Media clarity, pupillary dilation and patient cooperation sufficient to allow OCT testing and retinal photography.

Only one eye will be assessed in the study. If both eyes are eligible, the investigator will determine which eye will be entered into the study.

Exclusion Criteria:

  1. Previous intravitreal triamcinolone injection in study eye within 3 months of study injection.
  2. Use of more than two glaucoma medicines for study eye.
  3. Significant epiretinal membrane as judged by treating physician.
  4. Evidence of vitreomacular traction on OCT.
  5. Previous vitrectomy in study eye.
  6. Pregnancy (positive pregnancy test) or lactation.
  7. Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an intrauterine device (IUD), or contraceptive hormone implant or patch.
  8. Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated.
  9. Participation in another simultaneous IND trial.
  10. Treatment for CME with intravitreal Lucentis, Macugen, or Avastin within 6 weeks prior to enrollment in this study.
  11. Uncontrolled inflammation in the study eye.
  12. Current vitreous hemorrhage.
  13. Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye.
  14. Known allergy to any component of the study drug.
  15. Intraocular pressure > 25 mm Hg despite treatment with glaucoma medications.
  16. Blood pressure > 180/110 (systolic above 180 OR diastolic above 110). If blood pressure is brought below 180/110 by anti-hypertensive treatment, the subject can become eligible.
  17. Major non-ocular surgery planned during the next 6 months.
  18. Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated.
  19. No Avastin use permitted in fellow eye during study.
  20. Unwilling or unable to follow or comply with all study related procedures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00826618

United States, Florida
Bascom Palmer Eye Insitute
Miami, Florida, United States, 33136
Bascom Palmer of the Palm Beaches
Palm Beach Gardens, Florida, United States, 33418
Sponsors and Collaborators
University of Miami
Genentech, Inc.
Principal Investigator: Thomas A Albini, MD University of Miami

Responsible Party: Thomas Albini, Associate Professor of Clinical Ophthalmology, University of Miami Identifier: NCT00826618     History of Changes
Other Study ID Numbers: FVF4148s
First Posted: January 22, 2009    Key Record Dates
Results First Posted: August 26, 2014
Last Update Posted: August 26, 2014
Last Verified: August 2014

Keywords provided by Thomas Albini, University of Miami:
Cystoid Macular Edema

Additional relevant MeSH terms:
Macular Edema
Signs and Symptoms
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents